Does new knowledge allow to improve the diagnosis of mental disorders: the problem of anti-NMDA receptor encephalitis?

Abstract

A narrative review of research studies discusses the clinical features, differential diagnosis, and treatment of anti-NMDA receptor encephalitis. Special attention is given to the controversial aspects of the etiology and pathogenesis of this disorder. The need for further research into on the role of antibodies to NMDA receptors in the development of psychiatric disorders is emphasized.

Keywords

psychosis / affective disorders / antibodies / autoimmune diseases / autoimmune encephalitis

References

[1] Vitaliani R, Mason V, Ances B et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol. 2005;5(4):594–604. doi: 10.1002/ana.20614

[2] Vitaliani R., Mason V., Ances B. et al. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma // Ann. Neurol. 2005. Vol. 5. N. 4. P. 594–604. doi: 10.1002/ana.20614

[3] Dalmau J, Tuzun E, Wu H et al. Paraneoplastic anti-N-methyl-D-aspartate encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25–36. doi: 10.1002/ana.21050

[4] Dalmau J., Tuzun E., Wu H. et al. Paraneoplastic anti-N-methyl-D-aspartate encephalitis associated with ovarian teratoma // Ann. Neurol. 2007. Vol. 61. N. 1. P. 25–36. doi: 10.1002/ana.21050

[5] Zhao X, Teng Y, Ni J et al. Systematic review: Clinical characteristics of anti-N-methyl-D-aspartate receptor encephalitis. Front Hum Neurosci. 2023;17:1261638. doi: 10.3389/fnhum.2023.1261638

[6] Zhao X., Teng Y., Ni J. et al. Systematic review: Clinical characteristics of anti-N-methyl-D-aspartate receptor encephalitis // Front. Hum. Neurosci. 2023. Vol. 17. P. 1261638. doi: 10.3389/fnhum.2023.1261638

[7] Dalmau J, Armangué T, Planagumà J et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;11(18):1045–1057. doi: 10.1016/S1474-4422(19)30244-3

[8] Dalmau J., Armangué T., Planagumà J. et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models // Lancet Neurol. 2019. Vol. 11. N. 18. Р. 1045–1057. doi: 10.1016/S1474-4422(19)30244-3

[9] Murashko AA. Anti-NMDA receptor encephalitis mimic psychiatric disorders. Social and Clinical Psychiatry. 2022;32(4):59–67. (In Russ.)

[10] Мурашко А.А. Мимикрия: анти-NMDA-рецепторный энцефалит и психические расстройства // Социальная и клиническая психиатрия. 2022. Т. 32. №4. С. 59–67.

[11] Shmukler AB, Murashko AA. Practical recommendations for the diagnosis and treatment of patients with schizophrenia and other psychotic spectrum disorders with elevated levels of serum antibodies to NMDA receptors. Information letter. M.: National Research Center for Psychiatry and Narcology; 2022. 26 p. (In Russ.)

[12] Шмуклер А.Б., Мурашко А.А. Практические рекомендации по диагностике и терапии пациентов с шизофренией и другими расстройствами психотического спектра с повышенным уровнем сывороточных антител к NMDA-рецепторам / Информационное письмо. М.: Национальный медицинский исследовательский центр психиатрии и наркологии имени В.П. Сербского; 2022. 26 с.

[13] Gillinder L, Warren N, Hartel G et al. EEG findings in NMDA encephalitis — A systematic review. Seizure. 2019;65:20–24. doi: 10.1016/j.seizure.2018.12.015

[14] Gillinder L., Warren N., Hartel G. et al. EEG findings in NMDA encephalitis — A systematic review // Seizure. 2019. Vol. 65. Р. 20–24. doi: 10.1016/j.seizure.2018.12.015

[15] Blackman G, Lim MF, Pollak Th et al. The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: A systematic review and meta-analysis of individual patient data. J Neurol. 2022;269:5302–5311. doi: 10.1007/s00415-022-11224-6

[16] Blackman G., Lim M.F., Pollak Th. et al. The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: A systematic review and meta-analysis of individual patient data // J. Neurol. 2022. Vol. 269. P. 5302–5311. doi: 10.1007/s00415-022-11224-6

[17] Karyakina MV, Murashko AA. Cognitive impairment in patients with anti-NMDA receptor encephalitis. Social and Clinical Psychiatry. 2022;32(1):82–88. (In Russ.)

[18] Карякина М.В., Мурашко А.А. Когнитивные нарушения у пациентов с анти-NMDA-рецепторным энцефалитом // Социальная и клиническая психиатрия. 2022. Т. 32. №1. С. 82–88.

[19] McKeon GL, Robinson GA, Ryan AE et al. Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: A systematic review. J Clin Exper Neuropsychol. 2018;40(3):234–252. doi: 10.1080/13803395.2017.1329408

[20] McKeon G.L., Robinson G.A., Ryan A.E. et al. Cognitive outcomes following anti-N-methyl-D-aspartate receptor encephalitis: A systematic review // J. Clin. Exper. Neuropsychol. 2018. Vol. 40. N. 3. P. 234–252. doi: 10.1080/13803395.2017.1329408

[21] Murashko AA. Mental disorders in autoimmune encephalitis. Social and Clinical Psychiatry. 2021;31(1):74–79. (In Russ.)

[22] Мурашко А.А. Психические нарушения при аутоиммунных энцефалитах // Социальная и клиническая психиатрия. 2021. Т. 31. №1. С. 74–79.

[23] Al-Diwani A, Handel A, Townsend L et al. The psychopathology of NMDAR-antibody encephalitis in adults: A systematic review and phenotypic analysis of individual patient data. Lancet. Psychiatry. 2019;6(3):235–246. doi: 0.1016/S2215-0366(19)30001-X

[24] Al-Diwani A., Handel A., Townsend L. et al. The psychopathology of NMDAR-antibody encephalitis in adults: A systematic review and phenotypic analysis of individual patient data // Lancet. Psychiatry. 2019. Vol. 3. N. 6. P. 235–246. doi: 0.1016/S2215-0366(19)30001-X

[25] Wang W, Zhang L, Chi X-S et al. Psychiatric symptoms of patients with anti-NMDA receptor encephalitis. Front Neurol. 2020;10:1330. doi: 10.3389/fneur.2019.01330

[26] Wang W., Zhang L., Chi X.-S. et al. Psychiatric symptoms of patients with anti-NMDA receptor encephalitis // Front. Neurol. 2020. Vol. 10. Art. 1330. doi: 10.3389/fneur.2019.01330

[27] Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis. JAMA Neurol. 2013;70(9):1133–1139. doi: 10.1001/jamaneurol.2013.3216

[28] Kayser M.S., Titulaer M.J., Gresa-Arribas N., Dalmau J. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-D-aspartate receptor encephalitis // JAMA Neurol. 2013. Vol. 70. N. 9. P. 1133–1139. doi: 10.1001/jamaneurol.2013.3216

[29] Kawai H, Takaki M, Sakamoto S et al. Anti-NMDA-receptor antibody in initial diagnosis of mood disorder. Eur Neuropsychopharmacol. 2019;29(9):1041–1050. doi: 10.1016/j.euroneuro.2019.07.137

[30] Kawai H., Takaki M., Sakamoto S. et al. Anti-NMDA-receptor antibody in initial diagnosis of mood disorder // Eur. Neuropsychopharmacol. 2019. Vol. 29. N. 9. P. 1041–1050. doi: 10.1016/j.euroneuro.2019.07.137

[31] Spektor VA. The role of antibodies to NMDA-receptors in the development of affective disorders. Social and Clinical Psychiatry. 2023;33(2):82–90. (In Russ.)

[32] Спектор В.А. Роль антител к NMDA-рецепторам в развитии аффективных расстройств // Социальная и клиническая психиатрия. 2023. Т. 33. №2. С. 82–90.

[33] Leonhard K. Aufteilung der endogenen Psychosen und ihre differenzierte Aetiologie. M.: Practicheskaya medicina; 2010. 456 р. (In Russ.)

[34] Леонгард К. Систематика эндогенных психозов и их дифференцированная этиология. М.: Практическая медицина; 2010. 456 с.

[35] Komagamine T, Kanbayashi T, Suzuki K et al. “Atypical psychoses” and anti-NMDA receptor encephalitis: A review of literature in the mid-twentieth century. Psychiatry Clin Neurosci. 2022;76(2):62–63. doi: 10.1111/pcn.13317

[36] Komagamine T., Kanbayashi T., Suzuki K. et al. “Atypical psychoses” and anti-NMDA receptor encephalitis: A review of literature in the mid-twentieth century // Psychiatry Clin. Neurosci. 2022. Vol. 76. N. 2. P. 62–63. doi: 10.1111/pcn.13317

[37] Mitsuda H. Klinisch-erbbiologische Untersuchung der Schizophrenie. Psychiatr Neurol Jap. 1942;46: 297–362. (In Japanese; quoted by Komagamine T et al., 2022.)

[38] Mitsuda H. Klinisch-erbbiologische Untersuchung der Schizophrenie // Psychiatr. Neurol. Jap. 1942. Vol. 46. S. 297–362. (In Japanese; quoted by Komagamine T. et al., 2022.)

[39] Hatotani N, Ishida C, Yura R et al. Psychophysiological studies of atypical psychoses-endocrinological aspect of periodic psychoses. Folia Psychiatr Neurol Jap. 1962;16:248–292. (Quoted by Komagamine T et al., 2022.)

[40] Hatotani N., Ishida C., Yura R. et al. Psychophysiological studies of atypical psychoses-endocrinological aspect of periodic psychoses // Folia Psychiatr. Neurol. Jap. 1962. Vol. 16. P. 248–292. (Цит. по Komagamine T. et al., 2022.)

[41] Servén GE, Quintana BE, Ramírez MM et al. Cycloid psychosis as a psychiatric expression of anti-NMDAR encephalitis. A systematic review of case reports accomplished with the authors' cooperation. Brain Behav. 2021;11:e01980. doi: 10.1002/brb3.198

[42] Servén G.E., Quintana B.E., Ramírez M.M. et al. Cycloid psychosis as a psychiatric expression of anti-NMDAR encephalitis. A systematic review of case reports accomplished with the authors' cooperation // Brain Behav. 2021. Vol. 11. Р. e01980. doi: 10.1002/brb3.198

[43] Ehrenreich H. Autoantibodies against N-methyl-D-aspartate receptor 1 in health and disease. Curr Opin Neurol. 2018;31(3):306–312. doi: 10.1097/WCO.0000000000000546

[44] Ehrenreich H. Autoantibodies against N-methyl-D-aspartate receptor 1 in health and disease // Curr. Opin. Neurol. 2018. Vol. 31. N. 3. P. 306–312. doi: 10.1097/WCO.0000000000000546

[45] Gastaldi VD, Wilke JBH, Weidinger CA. Factors predisposing to humoral autoimmunity against brain-antigens in health and disease: Analysis of 49 autoantibodies in over 7000 subjects. Brain Behav Immunity. 2023;108:135–147. doi: 10.1016/j.bbi.2022.10.016

[46] Gastaldi V.D., Wilke J.B.H., Weidinger C.A. Factors predisposing to humoral autoimmunity against brain-antigens in health and disease: Analysis of 49 autoantibodies in over 7000 subjects // Brain. Behav. Immunity. 2023. Vol. 108. P. 135–147. doi: 10.1016/j.bbi.2022.10.016

[47] Shmukler AB, Ivashkina AA, Murashko AA. A case of anti-NMDA-receptor encephalitis presenting as febrile catatonia. Bulletin of Siberian Medicine. 2019;18(4):266–272. (In Russ.) doi: 10.20538/1682-0363-2019-4-266-272

[48] Шмуклер А.Б., Ивашкина А.А., Мурашко А.А. Случай анти-NMDA-рецепторного энцефалита с клинической картиной фебрильной кататонии // Бюллетень сибирской медицины. 2019. T. 18. №4. C. 266–272. doi: 10.20538/1682-0363-2019-4-266-272

[49] Kiryanova EM, Salnikova LI. Clinical case anti-NMDA receptor encephalitis. Social and Clinical Psychiatry. 2023;33(4):81–89. (In Russ.) doi: 10.34757/0869-4893.2023.33.4.010

[50] Кирьянова Е.М., Сальникова Л.И. Клинический случай анти-NMDA-рецепторного энцефалита // Социальная и клиническая психиатрия. 2023. Т. 33. №4. С. 81–89. doi: 10.34757/0869-4893.2023.33.4.010

[51] Davydovsky IV. The problem of causation in medicine (etiology). M.: Medgiz; 1962. 130 p. (In Russ.)

[52] Давыдовский И.В. Проблема причинности в медицине (этиология). М.: Медгиз; 1962. 130 с.

[53] Yu Y, Wu Y, Cao X et al. The clinical features and prognosis of anti-NMDAR encephalitis depends on blood brain barrier integrity. Mult Scler Relat Disord. 2021. Art. 102604. doi: 10.1016/j.msard.2020.102604

[54] Yu Y., Wu Y., Cao X. et al. The clinical features and prognosis of anti-NMDAR encephalitis depends on blood brain barrier integrity // Mult. Scler. Relat. Disord. 2021. Art. 102604. doi: 10.1016/j.msard.2020.102604

[55] Endres D, Meixensberger S, Dersch R et al. Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis. Transl Psychiatry. 2020;10(1):279. doi: 10.1038/s41398-020-00967-3

[56] Endres D., Meixensberger S., Dersch R. et al. Cerebrospinal fluid, antineuronal autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective psychosis // Transl. Psychiatry. 2020. Vol. 10. N. 1. P. 279. doi: 10.1038/s41398-020-00967-3

[57] Barkanova V, Shmukler AB. Disruption of the blood-brain barrier integrity and the development of movement disorders in patients with autoimmune diseases, characterized by the presence of psychopathological symptoms. Russian Psychiatric Journal. 2023;(3):91–103. (In Russ.)

[58] Барканова В., Шмуклер А.Б. Роль нарушения целостности гематоэнцефалического барьера в развитии двигательных нарушений при аутоиммунных заболеваниях, сопровождающихся психопатологической симптоматикой // Российский психиатрический журнал. 2023. №3. С. 91–103.

[59] Ma Y, Wang J, Guo S et al., Cytokine/chemokine levels in the CSF and serum of anti-NMDAR encephalitis: A systematic review and meta-analysis. Front Immunol. 2023;13:1064007. doi: 10.3389/fimmu.2022.1064007

[60] Ma Y., Wang J., Guo S. et al. Cytokine/chemokine levels in the CSF and serum of anti-NMDAR encephalitis: A systematic review and meta-analysis // Front. Immunol. 2023. Vol. 13. Art. 1064007. doi: 10.3389/fimmu.2022.1064007

[61] Nabizadeh F, Balabandian M, Sodeifian F et al. Autoimmune encephalitis associated with COVID-19: A systematic review. Mult Scler Relat Disord. 2022;62:103795. doi: 10.1016/j.msard.2022.103795

[62] Nabizadeh F., Balabandian M., Sodeifian F. et al. Autoimmune encephalitis associated with COVID-19: A systematic review // Mult. Scler. Relat. Disord. 2022. Vol. 62. Art. 103795. doi: 10.1016/j.msard.2022.103795

[63] Swayne A, Warren N, Prain K et al. Analysing triggers for anti-NMDA-receptor encephalitis including herpes simplex virus encephalitis and ovarian teratoma: Results from the Queensland Autoimmune Encephalitis cohort. Intern Med J. 2022;52(11):1943–1949. doi: 10.1111/imj.15472

[64] Swayne A., Warren N., Prain K. et al. Analysing triggers for anti-NMDA-receptor encephalitis including herpes simplex virus encephalitis and ovarian teratoma: Results from the Queensland Autoimmune Encephalitis cohort // Intern. Med. J. 2022. Vol. 52. N. 11. P. 1943–1949. doi: 10.1111/imj.15472

[65] Levite M. Glutamate receptor antibodies in neurological diseases: Anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: Epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. J Neural Transm (Vienna). 2014;121(8):1029–1075. doi: 10.1007/s00702-014-1193-3

[66] Levite M. Glutamate receptor antibodies in neurological diseases: Anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: Epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke // J. Neural. Transm. (Vienna). 2014. Vol. 121. N. 8. P. 1029–1075. doi: 10.1007/s00702-014-1193-3

[67] Gerosa M, Poletti B, Pregnolato F et al. Antiglutamate receptor antibodies and cognitive impairment in primary antiphospholipid syndrome and systemic lupus erythematosus. Front Immunol. 2016;7:5. doi: 10.3389/fimmu.2016.00005

[68] Gerosa M., Poletti B., Pregnolato F. et al. Antiglutamate receptor antibodies and cognitive impairment in primary antiphospholipid syndrome and systemic lupus erythematosus // Front. Immunol. 2016. Vol. 7. Art. 5. doi: 10.3389/fimmu.2016.00005

Funding

Правительство РФGovernment of the Russian Federation(123022000057-4)

RIGHTS & PERMISSIONS

Eco-Vector